A Phase 1, Randomized, Partially-Blind, Parallel-Group, Active and Placebo Controlled Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of Entecavir Extended Release (XR) in Healthy Subjects

Trial Profile

A Phase 1, Randomized, Partially-Blind, Parallel-Group, Active and Placebo Controlled Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of Entecavir Extended Release (XR) in Healthy Subjects

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs Entecavir (Primary)
  • Indications Hepatitis B
  • Focus Pharmacokinetics
  • Sponsors Aucta Pharmaceuticals
  • Most Recent Events

    • 05 Oct 2017 Planned End Date changed from 13 Nov 2017 to 28 Feb 2018.
    • 05 Oct 2017 Planned primary completion date changed from 6 Nov 2017 to 29 Dec 2017.
    • 05 Oct 2017 Planned initiation date changed from 6 Sep 2017 to 20 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top